Evidence map›Paper›PMID 41327172›Full record

ArticleBMC cancer2025

Context-dependent MAN1A1 protein expression in metastatic breast cancer progression predicts patient survival.

Nicole M Jenkinson, Sarah Hughes, Alexander Baras, Alan Meeker, Pedram Argani, Kristine Glunde

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicole M JenkinsonDivision of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University In Vivo Cellular and Molecular Imaging Center, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Traylor Building, Room 203, Baltimore, MD, 21205, USA.
Sarah HughesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexander BarasDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alan MeekerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pedram ArganiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kristine GlundeDivision of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University In Vivo Cellular and Molecular Imaging Center, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Traylor Building, Room 203, Baltimore, MD, 21205, USA. kglunde1@jhmi.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Reprogramming of creatine metabolism in breast cancer metastasisR01CA264901 · NCI · JOHNS HOPKINS UNIVERSITY · PI Kristine Glunde · 2022 to 2026
$1.8M
The Role of EpCAM Glycosylation in Breast Cancer MetastasisF30CA268849 · NCI · JOHNS HOPKINS UNIVERSITY · PI JENKINSON, NICOLE MARIE · 2023 to 2025
$161k
NCI NIH HHS F30 CA268849NCI NIH HHS R01 CA264901NIGMS NIH HHS T32 GM007309NIH HHS F30 CA268849NIH HHS R01 CA264901
6 · The paper itself

Abstract

backgroundAlterations in N-glycosylation are frequently observed in breast cancer metastasis but are not well understood. Recently, decreases in expression of the Golgi α-mannosidase I MAN1A1 have been linked to worse patient prognosis in breast cancer.

methodsTo examine MAN1A1 expression in breast cancer progression, we developed and conducted MAN1A1 immunostaining of breast cancer tissue microarrays (TMAs), which were analyzed using pathology-guided object classifiers, which identified normal breast epithelial cells, primary tumor cells, and metastatic tumor cells.

resultsMAN1A1 protein expression was significantly increased in primary tumor and local lymph node metastasis for a cohort of patients without distant metastases (N = 48). Changes in MAN1A1 protein expression along the metastatic path were context-dependent, as well as associated with survival for a rare, limited cohort of terminal metastatic breast cancer patients (N = 16). For these patients, an increase in MAN1A1 expression from normal breast to primary tumor was concomitant with decreased survival time (p = 0.032, hazard ratio = 2.68), as was a decrease in MAN1A1 expression from primary tumor to metastasis (p = 0.0018, hazard ratio = 3.45).

conclusionIn our pilot study, MAN1A1 protein expression is a significant actor in progression along the metastatic path, supporting further study into MAN1A1 as driver of breast cancer patient survival.

Indexed as

Biomarkers, TumorBreast NeoplasmsMannosidasesAdultAgedDisease ProgressionFemaleHumansLymphatic MetastasisMiddle AgedNeoplasm MetastasisPilot ProjectsPrognosisTissue Array AnalysisBiomarkers, TumorMannosidasesBreastCancerMAN1A1MannosidaseMetastasisN-glycanN-glycosylationTissue microarray

Identifiers

PMID41327172
PMCPMC12781482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.